May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title ARMOR: Phase 3/4 Double-Blind, Placebo-Controlled Clinical Study to Evaluate Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) Disease or condition NAFLD/NASH with Fibrosis Study type […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title HANMI: A Phase 2, Randomized, Double-Blind Study to Evaluate HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH; Protocol: HM-TRIA-201 Disease or […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title Genentech: PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BFKB8488A COMPARED WITH PLACEBO IN PATIENTS WITH NASH Disease […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title Alpine-4: Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title Madrigal-11: A Phase 3, Multinational, Double-Blind, Randomized,Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With NASH and Fibrosis to Resolve NASH and reduce Progression to […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Note: this study is at multiple sites in North Carolina Study title Viking: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF VK2809 ADMINISTERED FOR 52 […]
JOIN NOW